MX2016000464A - Incremento del potencial osteogenico de los injertos oseos. - Google Patents

Incremento del potencial osteogenico de los injertos oseos.

Info

Publication number
MX2016000464A
MX2016000464A MX2016000464A MX2016000464A MX2016000464A MX 2016000464 A MX2016000464 A MX 2016000464A MX 2016000464 A MX2016000464 A MX 2016000464A MX 2016000464 A MX2016000464 A MX 2016000464A MX 2016000464 A MX2016000464 A MX 2016000464A
Authority
MX
Mexico
Prior art keywords
enhancement
bone grafts
osteogenic potential
invention concerns
vivo treatment
Prior art date
Application number
MX2016000464A
Other languages
English (en)
Inventor
Jill Helms
Girija Dhamdhere
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2016000464A publication Critical patent/MX2016000464A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A61L27/3645—Connective tissue
    • A61L27/365—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Abstract

La presente invención se refiere al incremento de supervivencia celular y potencial osteogénico del injerto óseo mediante tratamiento ex vivo con un polipéptido Wnt, tal como un polipéptido Wnt liposómico. En particular, la invención se refiere al tratamiento ex vivo de injertos óseos con proteína Wnt3a humana, preferiblemente Wnt3a humana liposómica (LWnt3a).
MX2016000464A 2013-07-16 2014-07-16 Incremento del potencial osteogenico de los injertos oseos. MX2016000464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361957946P 2013-07-16 2013-07-16
PCT/US2014/046852 WO2015009829A2 (en) 2013-07-16 2014-07-16 Enhancement of osteogenic potential of bone grafts

Publications (1)

Publication Number Publication Date
MX2016000464A true MX2016000464A (es) 2016-04-07

Family

ID=52346837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000464A MX2016000464A (es) 2013-07-16 2014-07-16 Incremento del potencial osteogenico de los injertos oseos.

Country Status (12)

Country Link
US (4) US9301980B2 (es)
EP (1) EP3021943B1 (es)
JP (2) JP6557659B2 (es)
KR (1) KR102307174B1 (es)
CN (2) CN105431202B (es)
AU (2) AU2014290042B2 (es)
CA (1) CA2916898A1 (es)
GB (2) GB2578557B (es)
IL (1) IL243288B (es)
MX (1) MX2016000464A (es)
WO (1) WO2015009829A2 (es)
ZA (1) ZA201600095B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2994125C (en) 2015-07-31 2023-08-08 DePuy Synthes Products, Inc. Method of preparing an osteogenic bone graft
US11491262B2 (en) * 2018-04-19 2022-11-08 Paulo Jose PASQUALI Method of bone regeneration
US20210079079A1 (en) * 2018-05-02 2021-03-18 Ortheus, Inc. Systems and methods for local modulation of wnt signaling
CN111700881B (zh) * 2020-07-02 2021-05-18 四川大学 Wnt蛋白＼ZIF-8纳米复合体、其制备方法及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545412A (en) 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US5705655A (en) 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
EP0730405A4 (en) 1993-11-24 1997-02-19 Megabios Corp AMPHIPHILE GUANIDINE DERIVATIVES
NZ277614A (en) 1993-11-24 1998-05-27 Megabios Corp Piperazine-containing amphiphiles and their use in liposomes for delivering genetic material intracellularly
AU696881B2 (en) 1994-06-22 1998-09-24 Megabios Corporation Cationic amphiphiles
DE19521412A1 (de) 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
CA2419454A1 (en) * 2000-08-18 2002-02-28 Proskelia Regulator gene and system useful for the diagnosis and therapy of osteoporosis
US6723131B2 (en) * 2001-02-28 2004-04-20 The Cleveland Clinic Foundation Composite bone marrow graft material with method and kit
WO2005018549A2 (en) * 2003-08-12 2005-03-03 The Brigham And Women' S Hospital, Inc. Methods and compositions for tissue repair
US8343922B2 (en) * 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
CN1846793B (zh) * 2005-04-14 2011-08-03 南方医院 一种组织工程骨及其构建与应用
EP2134352A4 (en) * 2007-03-05 2011-05-25 Univ Leland Stanford Junior WNT COMPOSITIONS AND METHODS FOR THEIR USE
AU2008331808B2 (en) * 2007-03-16 2014-08-21 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
JP5458238B2 (ja) * 2007-11-30 2014-04-02 一郎 小野 臓器再生用デバイス
US8728805B2 (en) * 2008-08-22 2014-05-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US9511093B2 (en) * 2009-03-23 2016-12-06 The Texas A & M University System Compositions of mesenchymal stem cells to regenerate bone
WO2012034070A1 (en) * 2010-09-09 2012-03-15 The Board Of Trustees Of The Leland Stanford Junior University Use of liposomal wnt compositions to enhance osseointegration
US9241972B2 (en) * 2011-03-28 2016-01-26 The Board Of Trustees Of The Leland Stanford Junior University Use of Wnt agents to prevent hypoxic injury

Also Published As

Publication number Publication date
US11771803B2 (en) 2023-10-03
GB2578557B (en) 2020-09-02
ZA201600095B (en) 2021-09-29
IL243288A0 (en) 2016-02-29
GB2530224A (en) 2016-03-16
JP6897996B2 (ja) 2021-07-07
US9301980B2 (en) 2016-04-05
CN105431202A (zh) 2016-03-23
AU2014290042A1 (en) 2016-01-28
EP3021943A2 (en) 2016-05-25
KR102307174B1 (ko) 2021-10-01
IL243288B (en) 2021-01-31
AU2019222935B2 (en) 2021-09-09
GB2530224B (en) 2020-08-05
KR20160032125A (ko) 2016-03-23
US10568989B2 (en) 2020-02-25
US9925304B2 (en) 2018-03-27
CN111643733A (zh) 2020-09-11
GB201600149D0 (en) 2016-02-17
GB2578557A (en) 2020-05-13
US20180140743A1 (en) 2018-05-24
JP6557659B2 (ja) 2019-08-07
CN105431202B (zh) 2020-03-24
EP3021943A4 (en) 2017-02-15
US20170056556A1 (en) 2017-03-02
AU2014290042B2 (en) 2019-06-20
JP2016524989A (ja) 2016-08-22
CN111643733B (zh) 2023-07-28
AU2019222935A1 (en) 2019-09-19
JP2019177224A (ja) 2019-10-17
US20150050249A1 (en) 2015-02-19
EP3021943B1 (en) 2023-09-13
GB202001056D0 (en) 2020-03-11
WO2015009829A3 (en) 2015-11-12
WO2015009829A2 (en) 2015-01-22
US20200147267A1 (en) 2020-05-14
CA2916898A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
MX2016010293A (es) Micro-organoides, y metodos de fabricacion y usos los mismos.
SG10201810723VA (en) Improved t cell compositions
MX2022008085A (es) Moleculas peque?as contra cereblon para mejorar la funcion efectora de los linfocitos t.
MX369653B (es) Formulaciones de anticuerpos y proteinas.
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
WO2016070166A3 (en) Messenger una molecules and uses thereof
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX2019003619A (es) Formulaciones de bromocriptina.
EP4218809A3 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
MX359769B (es) Metodos para descelularizar huesos.
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
MX2015007584A (es) Triheptanoina para el tratamiento de la deficiencia del transportador de glucosa 1.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2016016756A (es) Terapia con células madre en patologías endometriales.
PH12017501070A1 (en) Peptides and their use in the treatment of skin
MX2019010558A (es) Peptidos y metodos para el tratamiento de diabetes.
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
AU2018262805A1 (en) Peptides for treatment of diabetes
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)